Figure 1From: Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responsesDurations of response for the 3 most common subtypes of PTCL in patients who achieved a response (CR or PR). â—¦ Indicates a censored patient.Back to article page